|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01875 TOT BIOPHARM-B
Nominal 
2.050 +0.100 (+5.128%) Profitability Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| ROAA (%) | 2.369% | -2.809% | -5.062% | -38.657% | -34.789% |
| ROAE (%) | 4.908% | -5.392% | -9.517% | -56.944% | -40.052% |
| Return on Capital Employed (%) | 3.179% | -3.618% | -5.059% | -58.118% | -49.028% |
Margin Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Gross Profit Margin (%) | -- | -- | -- | -- | -- |
| EBITDA Margin (%) | 3.756% | 1.277% | -0.235% | -295.399% | -1140.856% |
| Pre-tax Profit Margin (%) | 3.165% | -4.837% | -11.318% | -342.242% | -1282.726% |
| Net Profit Margin (%) | 3.165% | -4.837% | -11.289% | -342.242% | -1282.726% |
Liquidity Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Current Ratio (X) | 1.789 X | 1.812 X | 2.458 X | 1.173 X | 4.725 X |
| Quick Ratio (X) | 1.528 X | 1.483 X | 2.114 X | 1.060 X | 4.571 X |
Leverage Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Total Liabilities / Total Assets(%) | 51.639% | 51.849% | 43.311% | 52.822% | 9.175% |
| Total Debt / Total Assets (%) | 26.211% | 24.237% | 22.942% | 29.364% | 1.155% |
| Net Debt / Total Assets (%) | 0.942% | -0.417% | -10.161% | 7.851% | -34.019% |
| Total Debt / Shareholders' Funds (%) | 54.199% | 50.336% | 40.557% | 62.241% | 1.272% |
| Long Term Debt / Shareholders' Funds (%) | 44.487% | 44.107% | 29.764% | 18.177% | 1.045% |
| Net Debt / Shareholders' Funds (%) | 1.948% | -0.866% | -17.964% | 16.640% | -37.456% |
| Net Cash / (Debt) ($) | (14.212M) | 5.949M | 128.240M | (55.760M) | 218.127M |
| Net Cash / (Debt) per share ($) | (0.018) | 0.008 | 0.166 | (0.091) | 0.363 |
| Total Debt / Capital Employed (%) | 36.168% | 33.121% | 29.344% | 46.404% | 1.259% |
| Interest Coverage Ratio (X) | -- | N/A | N/A | N/A | N/A |
Efficiency Analysis
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Inventory Turnover (Day) | -- | -- | -- | -- | -- |
| Receivables Turnover (Day) | 40.269 Day | 31.541 Day | 25.118 Day | 31.732 Day | 67.163 Day |
| Payables Turnover (Day) | 13.130 Day | 14.423 Day | 22.369 Day | 110.516 Day | 292.214 Day |
| Remarks: | Real time quote last updated: 14/03/2025 12:01 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 34,757 |
| %Change | -- |
| EPS / (LPS) | RMB 0.050 |
| NBV Per Share (¥) | RMB 0.944 |